The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis.
Journal Information
Full Title: Ther Adv Hematol
Abbreviation: Ther Adv Hematol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"FM: Speaker bureau Blueprint, Novartis, AbbVie; FC: none; RZ: Honoraria Novartis and Blueprint, advisory board Blueprint, Cogent; LP: Speaker bureau Blueprint, Gilead, Janssen, Jazz, Novartis, Pfizer, Stemline-Menarini; DR: none; IT: none; MC: Speaker bureau Novartis; MB: none; AF: none; PG: none; AMV: Speaker bureau AOP, Blueprint, BMS, GSK, Incyte, Novartis."
Funding Disclosure
Evidence found in paper:
"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025